-transparent.png){kind=logo}
The concentration of lipids, lipoproteins and apolipoprotein A-I and B was measured in the plasma of 33 patients, enrolled in a double-blind, controlled trial of alprenolol in myocardial infarction, after one year on the study medication and again after 6 months off the medication. Sixteen patients received 200 mg alprenolol twice daily and 17 received placebo. There were no statistically significant differences between the parameters in the two groups after one year on medication. However, when medication was stopped, the ratio of apolipoprotein B to apolipoprotein A-I fell by 9% in the alprenolol group and increased by 2% in the placebo group. This difference was statistically significant. Our results suggest that alprenolol, a beta-blocker with weak intrinsic sympathomimetic effect, has slight effects on plasma lipoproteins. These effects were apparent only by measurements of apolipoproteins.
L U Gerdes, and
H J Jürgensen, and
P H Groot, and
O Faergeman
March 1990,
The American journal of cardiology,
L U Gerdes, and
H J Jürgensen, and
P H Groot, and
O Faergeman
January 1974,
Acta medica Scandinavica. Supplementum,
L U Gerdes, and
H J Jürgensen, and
P H Groot, and
O Faergeman
January 1974,
Acta medica Scandinavica. Supplementum,
L U Gerdes, and
H J Jürgensen, and
P H Groot, and
O Faergeman
January 1982,
Clinical chemistry,
L U Gerdes, and
H J Jürgensen, and
P H Groot, and
O Faergeman
April 1979,
Clinical pharmacology and therapeutics,
L U Gerdes, and
H J Jürgensen, and
P H Groot, and
O Faergeman
June 1980,
Atherosclerosis,
L U Gerdes, and
H J Jürgensen, and
P H Groot, and
O Faergeman
January 1991,
Biology of the neonate,
L U Gerdes, and
H J Jürgensen, and
P H Groot, and
O Faergeman
February 1987,
The American journal of clinical nutrition,
L U Gerdes, and
H J Jürgensen, and
P H Groot, and
O Faergeman
May 1988,
The American journal of medicine,
L U Gerdes, and
H J Jürgensen, and
P H Groot, and
O Faergeman
November 1979,
Clinical pharmacology and therapeutics,
